A study comparing drug-eluting stents (DES) and bare-metal stents (BMS) in Sweden found that DES were associated with a higher long-term risk of death compared to BMS. The study followed 6033 patients with DES and 13,738 patients with BMS over three years. While there was no significant difference in the composite outcome of death and myocardial infarction (MI) at three years, DES showed a higher event rate after six months, with a relative risk of 1.20 (95% CI, 1.05 to 1.37). At three years, the adjusted relative risk for death was 1.18 (95% CI, 1.04 to 1.35). The risk of death was 0.5 percentage points higher in patients with DES compared to BMS after six months, and the composite risk of death or MI was 0.5 to 1.0 percentage points higher per year. The long-term safety of DES needs to be confirmed in large, randomized trials. The study used data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and other national registries. Patients were followed for up to three years, and data on vital status, hospital admissions, and other outcomes were collected. The study adjusted for baseline characteristics and used propensity-score methods to account for non-randomized design. The results showed that DES had a lower event rate in the first six months but a higher rate thereafter. In the one-stent subgroup, the risk of death or MI was lower in the first six months but higher after that. The study also found that the risk of restenosis was significantly lower in patients with DES compared to BMS. The study highlights the long-term risks associated with DES, particularly the increased risk of death and MI after six months. While DES have been shown to reduce in-stent restenosis in randomized trials, their long-term safety remains a concern. The findings suggest that the use of DES should be carefully evaluated in future studies to determine their long-term benefits and risks. The study underscores the need for further research to clarify the long-term outcomes of DES and to ensure their safe and appropriate use.A study comparing drug-eluting stents (DES) and bare-metal stents (BMS) in Sweden found that DES were associated with a higher long-term risk of death compared to BMS. The study followed 6033 patients with DES and 13,738 patients with BMS over three years. While there was no significant difference in the composite outcome of death and myocardial infarction (MI) at three years, DES showed a higher event rate after six months, with a relative risk of 1.20 (95% CI, 1.05 to 1.37). At three years, the adjusted relative risk for death was 1.18 (95% CI, 1.04 to 1.35). The risk of death was 0.5 percentage points higher in patients with DES compared to BMS after six months, and the composite risk of death or MI was 0.5 to 1.0 percentage points higher per year. The long-term safety of DES needs to be confirmed in large, randomized trials. The study used data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and other national registries. Patients were followed for up to three years, and data on vital status, hospital admissions, and other outcomes were collected. The study adjusted for baseline characteristics and used propensity-score methods to account for non-randomized design. The results showed that DES had a lower event rate in the first six months but a higher rate thereafter. In the one-stent subgroup, the risk of death or MI was lower in the first six months but higher after that. The study also found that the risk of restenosis was significantly lower in patients with DES compared to BMS. The study highlights the long-term risks associated with DES, particularly the increased risk of death and MI after six months. While DES have been shown to reduce in-stent restenosis in randomized trials, their long-term safety remains a concern. The findings suggest that the use of DES should be carefully evaluated in future studies to determine their long-term benefits and risks. The study underscores the need for further research to clarify the long-term outcomes of DES and to ensure their safe and appropriate use.